Bailey Gregory Acquires Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Shares


Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) finished Thursday with an addition of $0.8 to close at $152.00, an upside of 0.53 percent. An average of 980,394 shares of common stock have been traded in the last five days. There was a gain of $1.00 in the past week, and it reached a new high 5 times over the past 12 months. The last 20 days have seen an average of 725,923 shares traded, while the 50-day average volume stands at 582,455.

BHVN stock has increased by 2.13% in the last month. The company shares reached their 1-month lowest point of $148.06 on 08/24/22. With the stock rallying to its 52-week high on 09/23/22, shares of the company touched a low of $79.01 and a high of $151.51 in 52 weeks. It has reached a new high 31 times so far this year and achieved 9.72% or $14.26 in price. In spite of this, the price is up 0.32% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Insider Transactions

136 days have passed since Biohaven Pharmaceutical Holding Company Ltd. (BHVN) last reported insider trading activity. Clark George C., who is VP, Chief Accounting Officer, most recently acquired $4,200 shares at $141.50 per share on May 10. In this transaction, the insider spent $594,300. VP, Chief Accounting Officer, Clark George C., disposed of 9,375 shares at a price of $117.01 on Jan 19. The insider now owns more than $1,097,003 worth of shares. Prior to that, Director GREGORY JULIA P went on to Sale 12,000 shares at $125.00 each on Dec 20. An amount of $1,500,000 was transacted.

Valuation Metrics

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stock’s beta is 1.04. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 12.59.

Financial Health

The quick ratio of Biohaven Pharmaceutical Holding Company Ltd. for the three months ended June 29 was 1.60, and the current ratio was 1.70, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $370.85 million compared to revenue of $462.51 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Biohaven Pharmaceutical Holding Company Ltd.’s return on assets was -82.30%.

Earnings Surprise

For the three-month period that ended June 29, Biohaven Pharmaceutical Holding Company Ltd. had $317.68 million in cash and short-term investments compared to $764.98 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$441.39 million in the quarter, while revenues were grew 52.28%. The analyst consensus anticipated Biohaven Pharmaceutical Holding Company Ltd.’s latest quarter earnings to come in at -$2.58 per share, but it turned out to be -$6.21, a -140.70% surprise. For the quarter, EBITDA amounted to -$284.22 million. Shareholders own equity worth $71.5 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Biohaven Pharmaceutical Holding Company Ltd. (BHVN) price momentum. RSI 9-day as of the close on 22 September was 84.77%, suggesting the stock is Overbought, with historical volatility in this time frame at 2.89%.

As of today, BHVN’s price is $151.38 +0.66% or $1.00 from its 5-day moving average. BHVN is currently trading +1.88% higher than its 20-day SMA and +62.61% higher than its 100-day SMA. However, the stock’s current price level is +4.88% above the SMA50 and +44.64% above the SMA200.

The stochastic %K and %D were 90.22% and 88.47%, respectively, and the average true range (ATR) was 0.55. With the 14-day stochastic at 98.93% and the average true range at 0.57, the RSI (14) stands at 81.18%. The stock has reached 0.24 on the 9-day MACD Oscillator while the 14-day reading was at 0.51.

Analyst Ratings

Piper Sandler downgraded Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Overweight. The consensus rating for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BHVN, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.

What is BHVN’s price target for the next 12 months?

Analysts predict a range of price targets between $148.50 and $158.00, with a median target of $148.75. Taking a look at these predictions, the average price target given by analysts for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stock is $151.00.


Please enter your comment!
Please enter your name here